Library

This study evaluated the physicochemical compatibility of six APIs (17-a-estradiol, betamethasone, finasteride, melatonin, prednicarbate, spironolactone) in TrichoFoam™, a foaming vehicle for personalized alopecia treatments. Stability studies showed APIs remained effective over defined durations, supporting TrichoFoam™ as a promising platform for tailored, patient-friendly alopecia therapies, enhancing adherence and outcomes.

A study on Cleoderm™, a semi-solid vehicle for acne treatment, evaluated its effectiveness and acceptance in a split-face trial of 10 patients. Results showed Cleoderm™ outperformed a commercial vehicle base in 80% of cases, offering better outcomes and comfort. Compounded formulations may enhance personalized acne therapy.

Pharmaceutical compounding companies face challenges in scaling operations to meet patient needs, particularly due to the 14-day sterility test delaying personalized medications. Fagron Sterile Services (FSS) addresses these issues by incorporating new technologies, streamlining processes, and improving speed while maintaining safety and compliance.

This study assessed the physical, chemical, and microbiological stability of active pharmaceutical ingredients in TrichoSol™ for alopecia treatments. HPLC and antimicrobial testing determined beyond-use dates (BUDs) ranging from 90 to 180 days for various compounds, including cetirizine hydrochloride, dutasteride, hydrocortisone acetate, nicotinamide, progesterone, and pyridoxine hydrochloride.

This study evaluated the compatibility and stability of APIs in Cleoderm™ using HPLC and forced degradation studies. Adapalene, dapsone, and hydroquinone formulations showed 180-day beyond-use dates with no physical or chemical changes. Microbiological tests confirmed preservative efficacy, highlighting Cleoderm™ as a reliable vehicle for dermatological preparations, particularly for acne and inflammatory dermatoses.

A new compounding topical solution (CTS) was developed for personalized alopecia treatment. It showed clinical tolerability with no irritation or phototoxic effects. CTS is compatible with active ingredients and may promote hair growth by enhancing fibroblast proliferation and gene expression. It offers a potential alternative or complement for alopecia management.

A new Compounding Cream Base (CCB) was developed as a topical acne treatment. It showed clinical tolerability with no irritation, comedogenic, or sensitizing effects. CCB may reduce sebum, lipid oxidation, microbial growth, and inflammation. It is compatible with active ingredients, supporting personalized acne therapy in dermatology practices.

The study on Imuno TF® found that it increased CD8+ T-cell frequency and boosted IL-2, IL-7, and IFN-γ levels, while reducing Th2 cytokines IL-4, IL-5, and IL-13. CD4+ T-cell frequency and IL-35 levels were unchanged, suggesting Imuno TF® promotes a Th1-dominant immune response.

Androgenetic alopecia (AGA) is a common form of hair loss affecting men and women, primarily driven by dihydrotestosterone (DHT). Recent research has identified genetic markers linked to AGA, aiding in personalized treatments. Pharmacogenetics and RNA interference (RNAi) technologies are emerging as promising avenues for developing more effective, individualized AGA therapies.

Labial adhesions in prepubertal girls result from inflammation of non-estrogenized labia minora. Traditional treatment uses topical estrogen, but this case showed successful recovery with estriol and testosterone in Pentravan, a transdermal cream. This suggests that androgens may aid in treating labial adhesions that are resistant to conventional therapies without side effects.